These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 34686915

  • 1. Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children.
    Vaz de Castro PAS, Bitencourt L, Pereira BWS, Lima AQR, Hermida HS, Moreira Neto CR, Mestriner MD, Simões E Silva AC.
    Pediatr Nephrol; 2022 Mar; 37(3):499-508. PubMed ID: 34686915
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
    Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S.
    Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007751. PubMed ID: 21975774
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis.
    Cheng J, Zhang X, Tian J, Li Q, Chen J.
    Int J Clin Pract; 2012 Oct 05; 66(10):917-23. PubMed ID: 22994326
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of traditional Chinese medicine versus angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and their combinations in the treatment of IgA nephropathy: a systematic review and network meta-analysis.
    Ma S, Jiang Y, Qian L, Wang M, Xu S, Wang G.
    Front Pharmacol; 2024 Oct 05; 15():1374377. PubMed ID: 38576485
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Non-immunosuppressive treatment for IgA nephropathy.
    Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GF.
    Cochrane Database Syst Rev; 2011 Mar 16; (3):CD003962. PubMed ID: 21412884
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Renin-Angiotensin Aldosterone System Inhibitor in Patients with IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.
    Zhao Y, Fan H, Bao BY.
    Iran J Public Health; 2019 Sep 16; 48(9):1577-1588. PubMed ID: 31700813
    [Abstract] [Full Text] [Related]

  • 11. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH, Guan CJ, Li LY, Gan P.
    Ann Palliat Med; 2022 Mar 29; 11(3):1093-1101. PubMed ID: 35365039
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.
    Sun LJ, Shan JP, Cui RL, Yuan WJ, Jiang GR.
    Int Urol Nephrol; 2017 Jun 29; 49(6):1049-1056. PubMed ID: 28283858
    [Abstract] [Full Text] [Related]

  • 14. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R, Rios P, Baldovinos G, Chichet MA, Perg N, Sola L, Saona G, De Souza N, Lamadrid V, Gadola L.
    Nephron; 2019 Jun 29; 143(2):100-107. PubMed ID: 31203280
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy.
    Sun L, Zi X, Wang Z, Zhang X.
    BMC Nephrol; 2023 Mar 22; 24(1):63. PubMed ID: 36949400
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007004. PubMed ID: 19588415
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical efficacy and safety of astragalus injection combined with ACEI/ARB in the treatment of diabetic kidney disease: Protocol for a systematic review and meta-analysis.
    Zhu Z, Zhang Q, Liu L, Bao P, Liu S, Song C, Yang W, Nan Z.
    Medicine (Baltimore); 2022 Dec 09; 101(49):e31490. PubMed ID: 36626537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.